Goodwill and intangible assets as of March 31, 2026 and December 31, 2025 were comprised of the following:


	March 31, 2026
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Brand name	25 years	$	952,000	$	(237,153)	$	714,847
Product formulations	15 years	136,500		(56,556)		79,944
Customer relationships	20 years	53,000		(16,507)		36,493
Software	3-7 years	11,355		(7,775)		3,580
Total finite-lived intangibles		1,152,855		(317,991)		834,864
Goodwill	Indefinite	168,300		—		168,300
Total goodwill and other intangibles		$	1,321,155	$	(317,991)	$	1,003,164


	December 31, 2025
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Brand name	25 years	$	952,000	$	(227,636)	$	724,364
Product formulations	15 years	136,500		(54,281)		82,219
Customer relationships	20 years	53,000		(15,841)		37,159
Software	3-7 years	11,217		(7,138)		4,079
Total finite-lived intangibles		1,152,717		(304,896)		847,821
Goodwill	Indefinite	168,300		—		168,300
Total goodwill and other intangibles		$	1,321,017	$	(304,896)	$	1,016,121

The amortization of the Company’s brand name, customer relationships and software is recorded to Amortization of other intangible assets in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. A portion of Amortization of patented formulations is capitalized to Inventory in the Condensed Consolidated Balance Sheets, and the remainder is recorded to Amortization of patented formulations in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.

Amortization of the Company’s definite-lived intangible assets for the three months ended March 31, 2026 and 2025 was as follows:


	Three Months Ended March 31,
		2026		2025
Amortization expense, patented formulations		$	2,416	$	2,392

Amortization expense, brand name and customer relationships		10,183		10,182
Amortization expense, software		637		711
Amortization expense, other intangible assets		$	10,820	$	10,893

Amortization expense, patented formulations capitalized to inventory		$	(141)	$	(118)